Cabergoline

Administration

  • Type: Dopamine Agonist
  • Dosage Forms: Tab 0.5mg
  • Routes of Administration: Oral
  • Common Trade Names: Dostinex

Adult Dosing

Hyperprolactinemia

  • 0.25-1 mg PO 2x/wk
    • Start 0.25mg 2x/wk, increase q4wk by 0.25mg 2x/wk
    • Max: 1 mg 2x/wk

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

  • Pregnancy Rating: B: No teratogenicity at 55x MRHD
  • Lactation risk: Avoid use while breastfeeding

Renal Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult:
    • Child-Pugh Class C: Caution advised
  • Pediatric: Unavailable

Contraindications

  • Allergy to class/drug
  • Hypersensitivity to ergot derivatives
  • Cardiac valvular fibrosis
  • Pericardial fibrosis
  • Pulmonary fibrosis
  • Retroperitoneal fibrosis
  • Hypertension, uncontrolled
  • Breastfeeding
  • Hepatic impairment

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 63-69 hrs
  • Metabolism: Liver
  • Excretion: Feces 60%, urine 22% (<4% unchanged)

Mechanism of Action

  • Stimulates dopamine D2 receptors to inhibit prolactin secretion

Comments

See Also

References

Authors:

Jonathan Warren